康休(CXO)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

CXO 康休

退市 01-15 16:00:00 EST

65.60

+0.00

0.00%

最高65.60	最低65.60	成交量0.00
今开65.60	昨收65.60	日振幅0.00%
总市值127.60亿	流通市值126.27亿	总股本1.95亿
成交额0.00	换手率0.00%	流通股本1.92亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"CXO","market":"US","secType":"STK","nameCN":"康休","latestPrice":65.6,"timestamp":1610744400000,"preClose":65.6,"halted":4,"volume":0,"delay":0,"changeRate":0,"floatShares":192489259,"shares":194506801,"eps":-52.266872,"marketStatus":"退市","change":0,"latestTime":"01-15 16:00:00 EST","open":65.6,"high":65.6,"low":65.6,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-52.266872,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1776326400000},"marketStatusCode":5,"adr":0,"adrRate":0,"listingDate":1186113600000,"exchange":"NYSE","adjPreClose":65.6,"dividendRate":0.011052,"volumeRatio":0},"requestUrl":"/m/hq/s/CXO","defaultTab":"news","newsList":[{"id":"2627257476","title":"东方证券：医药生物行业CXO景气上行 重视安评弹性和龙头重估","url":"https://stock-news.laohu8.com/highlight/detail?id=2627257476","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627257476?lang=zh_cn&edition=full","pubTime":"2026-04-16 09:19","pubTimestamp":1776302394,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，东方证券发布研报称，从医药生物业CXO景气度指标最新数据来看：2026Q1，国内融资向好趋势加强，早期研发管线备受青睐。订单端：安评限速，龙头重估1）安评：订单加速，猴子成瓶颈。临床前CRO，尤其是安全性评价，是本轮BD驱动的早期研发最受益方向。需求火热叠加实验猴供给受限，将会带来实验猴和CRO服务价格双升，成为新一轮国内创新药上行周期中弹性最大的细分方向；2）CDMO：全球冠军，近在咫尺。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1429153.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["600958","163118","CXO","BK1147","BK0012","000808.SH","03958","BK0276","BK0028","BK0183","BK1564","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627325669","title":"A股药企薪酬图鉴 创新药、CXO、高端医疗器械赛道人均薪酬领先","url":"https://stock-news.laohu8.com/highlight/detail?id=2627325669","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627325669?lang=zh_cn&edition=full","pubTime":"2026-04-16 07:00","pubTimestamp":1776294000,"startTime":"0","endTime":"0","summary":"随着A股年报相继出炉，各企业年薪再次成为焦点。截至2026年4月初，A股已有130家医药生物上市公司完整披露2025年人均薪酬数据。同花顺问财数据显示，医药行业内部薪酬分化极为显著，创新药、CXO、高端医疗器械三大赛道凭借高研发投入与技术壁垒，人均薪酬遥遥领先；而传统仿制药、中药、医药流通等领域则深陷薪酬洼地，行业最高与最低企业年薪差距超8倍。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/roll/2026-04-16/doc-inhurtwq7427621.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2026-04-16/doc-inhurtwq7427621.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1100","09997","BK1574","CXO","BK1222","BK1161","399300","06978","159883","159982","159992","09996","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627286159","title":"结构性分化复苏趋势明显，触底反弹的内需成头部CXO增长的“关键先生”","url":"https://stock-news.laohu8.com/highlight/detail?id=2627286159","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627286159?lang=zh_cn&edition=full","pubTime":"2026-04-15 19:06","pubTimestamp":1776251203,"startTime":"0","endTime":"0","summary":"CDMO赛道回归增长轨道受益于新分子需求快速增长及国内市场在BD驱动下的显著改善，2025年国内CXO公司订单整体处于环比持续向好的趋势，其中CDMO企业表现较其他细分赛道更为亮眼。根据国金证券统计数据，国内头部CDMO企业在2025年的订单增量均有出色表现。截至报告期末，公司待执行合同金额达182亿元，同比增长15.4%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1428929.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["CXO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627623478","title":"中信建投：持续看好CXO板块成长空间","url":"https://stock-news.laohu8.com/highlight/detail?id=2627623478","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627623478?lang=zh_cn&edition=full","pubTime":"2026-04-15 07:42","pubTimestamp":1776210169,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，中信建投证券发布研报称，海外投融资大环境进入季度间波动，不同阶段、不同疾病领域的CXO服务需求进一步分化，国内投融资活动景气度持续上行，弹性更强，持续看好CXO板块成长空间。AI制药双刃剑，研发及临床端存在分化，生产端整体利好：AI对制药及与医药外包行业虽然影响短期有限、但市场对新技术对长期的行业发展变革的影响已初步达成共识。积极布局AI技术的公司有望在新的产业趋势下延续生命周期、看到新的机会。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1428584.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["CXO","BK0276","601066"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627338194","title":"申万宏源：26年一季报披露期临近 关注创新药、CXO及上游","url":"https://stock-news.laohu8.com/highlight/detail?id=2627338194","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627338194?lang=zh_cn&edition=full","pubTime":"2026-04-13 16:10","pubTimestamp":1776067851,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，申万宏源发布研报称，截止至4月12日共有8家医药上市公司发布2026Q1业绩预告，其中6家利润同比增长，2家同比下滑。从细分板块来看，创新药、CXO及上游2026Q1的业绩表现有望超预期，重点推荐。从细分板块来看，创新药、CXO及上游2026Q1的业绩表现有望超预期其中，CXO板块的业绩增长主要得益于全球创新药行业景气度持续向好，行业新签订单呈现良好增长，国内外医药投融资景气度持续上行。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1427703.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0012","BK1161","BK0028","BK0276","CXO","BK0188","BK1564","06806","06978","BK0183","BK1147","000166","159992","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626162468","title":"西南证券：风险出清+双轮驱动 CXO有望开启景气上行周期","url":"https://stock-news.laohu8.com/highlight/detail?id=2626162468","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2626162468?lang=zh_cn&edition=full","pubTime":"2026-04-10 15:20","pubTimestamp":1775805627,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，西南证券发布研报称，2026年一季度，CXO板块风险出清、业绩分化、双轮驱动，板块有望进入新一轮景气上行周期。2026年一季度，CXO板块风险出清、业绩分化、双轮驱动：美国政策不确定性缓和，地缘压制消退、估值修复动力足;龙头(药明系)与CDMO业绩高增、临床CRO企稳，结构性行情显著;海外研发回暖+国内创新药市场修复共振，订单饱满锁定2026-2027年增长，板块有望进入新一轮景气上行周期。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1427015.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0188","600369","BK0183","BK0012","BK0276","BK0028","CXO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625917325","title":"创新药与CXO联袂走强：共振修复后市走势如何？","url":"https://stock-news.laohu8.com/highlight/detail?id=2625917325","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625917325?lang=zh_cn&edition=full","pubTime":"2026-04-08 17:44","pubTimestamp":1775641440,"startTime":"0","endTime":"0","summary":"4月以来，A股医药板块迎来全面回暖，再现一波“吃药”行情。其中A股医药板块迎来全面回暖，创新药与CXO（医药研发及生产外包）两大核心赛道联袂上演强势反弹行情，形成鲜明的产业链共振效应，成为市场资金布局的核心焦点。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604083698149210.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604083698149210.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1574","06978","159992","BK1161","CXO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625788996","title":"国信证券：全球生物医药投融资复苏 助推CXO行业需求向好","url":"https://stock-news.laohu8.com/highlight/detail?id=2625788996","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625788996?lang=zh_cn&edition=full","pubTime":"2026-04-08 10:19","pubTimestamp":1775614767,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，国信证券发布研报称，全球生物医药投融资明确复苏，2025年融资额同比增长4%，为CXO行业注入增长动力。CDMO方面，全球药品市场的平稳增长为CDMO行业筑牢需求根基，新分子疗法的爆发式增长更开辟了核心增量空间；CRO方面，作为研发链条的核心环节，其受投融资复苏的驱动更为直接，业绩兑现的确定性与增长弹性显著增强，行业景气度持续上行。临床前CRO领域，实验动物相关订单已率先触底反弹，后续增长确定性增强。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1425737.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["CXO","161726","BK0028","BK0183","BK4588","BK4585","399441","BK0188","BK4581","002736","BK0276","XBI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624524244","title":"中金：把握外需韧性兑现与内需触底复苏 坚定看好当前CXO板块布局机会","url":"https://stock-news.laohu8.com/highlight/detail?id=2624524244","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624524244?lang=zh_cn&edition=full","pubTime":"2026-04-02 11:30","pubTimestamp":1775100600,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，中金发布研报称，坚定看好当前CXO板块的布局机会。中金主要观点如下：事件CXO龙头公司2025年年报陆续披露：1)海外需求驱动的CDMO公司订单、业绩与产能投放延续良好经营态势，2026 年收入普遍指引双位数增长，彰显管理层信心;2)内需导向的临床CRO、安评CRO显现“订单量价齐修复”的复苏信号，从“订单修复”向“业绩兑现”阶段过渡，2026 年有望在订单执行带动下逐步传导至利润表。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1424434.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["CXO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623379186","title":"CXO概念股强势 凯莱英(06821)涨13.85% 机构认为CXO基本面拐点已经出现","url":"https://stock-news.laohu8.com/highlight/detail?id=2623379186","media":"金吾财讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623379186?lang=zh_cn&edition=full","pubTime":"2026-03-31 10:23","pubTimestamp":1774923794,"startTime":"0","endTime":"0","summary":"金吾财讯 | CXO概念股强势，凯莱英(06821)涨13.85%，昭衍新药(06127)涨7.34%，药明生物(02269)涨5.99%，康龙化成(03759)涨4.54%，药明康德(02359)涨4.12%，泰格医药(03347)涨2.89%，金斯瑞生物科技(01548)涨1.09%。浙商医药团队分析指出，在CXO产业持续出清，股价相对低位背景下，看好本土头部CDMO企业和受益国内需求复苏CRO企业底部投资机会。从财务、需求和供给数据分析，该机构认为CXO基本面拐点已经出现，并有望持续复苏。","market":"fut","thumbnail":"https://static.szfiu.com/news/20241108/YjA5ZTU5M2U3ZjIyNGI4Mzk2MWM1NGUyNWZkZjFmMjE3MzEwNTIzMzcxNTY=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/YjA5ZTU5M2U3ZjIyNGI4Mzk2MWM1NGUyNWZkZjFmMjE3MzEwNTIzMzcxNTY=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1977810","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0348825331.USD","LU0823426308.USD","LU3063872942.SGD","03347","LU0823426480.USD","HK0000306685.HKD","LU0516422366.SGD","LU0359201612.USD","LU1880383366.USD","IE00B0JY6N72.USD","LU0588546209.SGD","LU0856984785.SGD","06127","LU0456827905.SGD","LU0979878070.USD","LU0456846285.SGD","BK1576","LU1794554557.SGD","LU1328615791.USD","LU0516423091.SGD","LU0052750758.USD","LU0516423174.USD","LU0307460666.USD","LU0051755006.USD","LU0348735423.USD","LU0417516738.SGD","HK0000306701.USD","BK1521","LU0516422440.USD","LU2045819591.USD","CXO","03759","LU0320764599.SGD","LU0326950275.SGD","LU0572944931.SGD","LU0043850808.USD","02359","LU1688375341.USD","BK1589","LU0181495838.USD","LU1242518857.USD","01548","LU0327786744.USD","LU1046422090.SGD","002821","LU0819121731.USD","LU0039217434.USD","LU0140636845.USD","02269","06821"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621095723","title":"【券商聚焦】交银国际：CXO行情持续回暖 料板块估值倍数合理","url":"https://stock-news.laohu8.com/highlight/detail?id=2621095723","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621095723?lang=zh_cn&edition=full","pubTime":"2026-03-23 10:25","pubTimestamp":1774232735,"startTime":"0","endTime":"0","summary":"金吾财讯 | 交银国际表示，多重利好因素共振下，2025年以来CXO行情持续回暖。该机构建议重点关注标的细分赛道成长力、核心能力布局、盈利和订单增长能见度、地缘风险敞口及估值上升空间。基于此，该机构首推药明合联，首次覆盖并重点推荐凯莱英和康龙化成。","market":"fut","thumbnail":"https://static.szfiu.com/news/20250106/ZDQ3YWRiNzU2MjI5OWUwYTllMmZlMTAyNzEyNzQzMTU2MQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250106/ZDQ3YWRiNzU2MjI5OWUwYTllMmZlMTAyNzEyNzQzMTU2MQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1977006","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","BK1583","09926","09688","BK1500","LU0348767384.USD","LU1303224171.USD","IE00BPRC5H50.USD","01789","02367","LU0348784397.USD","LU0540923850.HKD","02228","LU2476274720.SGD","03329","BK1588","LU1770034418.SGD","LU2488822045.USD","02268","LU0348766576.USD","LU0634319403.HKD","03933","LU1794554557.SGD","06160","LU2399975544.HKD","BK1161","LU0307460666.USD","BK1197","01099","LU1115378108.SGD","LU0348735423.USD","LU0417516571.SGD","LU0417516738.SGD","LU0417516902.SGD","BK1617","CXO","LU2778985437.USD","BK1141","BK1207","01530","BK1191","BK1585","BK1593","LU2328871848.SGD","LU0348827113.USD","IE00B543WZ88.USD","LU2476274308.USD","02196","LU1719994722.HKD","06821"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620689789","title":"海纳医药三度冲击IPO：现金流吃紧、业绩持续下滑，仿制药CXO的故事不好讲了","url":"https://stock-news.laohu8.com/highlight/detail?id=2620689789","media":"新浪证券","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620689789?lang=zh_cn&edition=full","pubTime":"2026-03-20 16:48","pubTimestamp":1773996480,"startTime":"0","endTime":"0","summary":"国内CXO行业景气度乍暖还寒之际，又一家“卖水人”顶着寒风冲刺港股IPO。南京海纳医药科技股份有限公司近日递表港交所，这已是该公司三年内第三次向资本市场发起冲击。此前，海纳医药经历过创业板IPO折戟，也曾试图“卖身”成都先导实现曲线上市未果，如今在现金流日益紧绷、业绩持续下滑的背景下，火速转道港股。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/aigcy/2026-03-20/doc-inhrrrew0753832.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["09939","BK1515","159399","CXO","159938","BK1161","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620041459","title":"国信证券：CXO与器械板块机会显现 关注创新药产业链及低估值板块","url":"https://stock-news.laohu8.com/highlight/detail?id=2620041459","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620041459?lang=zh_cn&edition=full","pubTime":"2026-03-17 09:45","pubTimestamp":1773711919,"startTime":"0","endTime":"0","summary":"近期，国产创新药在学术会议上读出优秀的临床数据，建议关注二季度的ASCO等重磅学术会议。","market":"fut","thumbnail":"https://img.zhitongcaijing.com/image/20260317/20260317093554_26324.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20260317/20260317093554_26324.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1414694.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["06978","159992","BK1574","BK0183","002736","CXO","BK1161","BK0276","BK0028","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618601607","title":"万联证券：投融资与出海双轮驱动 CXO迎来景气度修复与全球化新周期","url":"https://stock-news.laohu8.com/highlight/detail?id=2618601607","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618601607?lang=zh_cn&edition=full","pubTime":"2026-03-10 10:50","pubTimestamp":1773111055,"startTime":"0","endTime":"0","summary":"医疗健康领域投融资金额持续增加2025年，全球共完成医疗健康领域一级市场投融资1930 笔，累计融资632亿美元，融资金额同比回升8.6%；中国医疗健康产业一级市场共达成797笔投融资交易，累计融资97亿美元，融资金额同比回升32.9%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1411998.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["161027","CXO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616242408","title":"绩优股扛旗，药明系CXO领衔，医疗ETF、港股通医疗华宝ETF双双回血！企稳信号出现？","url":"https://stock-news.laohu8.com/highlight/detail?id=2616242408","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616242408?lang=zh_cn&edition=full","pubTime":"2026-03-01 19:42","pubTimestamp":1772365320,"startTime":"0","endTime":"0","summary":"2月27日，A股医疗板块全天飘红，全市场规模最大医疗ETF盘中上探1.14%，成功收复年线，成交3.84亿元。场内持续溢价交易，显示买盘态度积极，此前3日512170累获逾1.9亿元净申购。　　绩优股惠泰医疗领涨8.24%，该公司业绩快报显示，2025年营收、归母净利润及扣非归母净利润均实现同比20%以上增长。　　港股医疗板块连跌多日后终于迎来反弹，港股通医疗ETF华宝下探历史新低后回升，日线终结六连阴。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2026-03-01/doc-inhpnwmf5292913.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["FDN","BK4550","VT","CXO","512170","159828","BK4588","BK4585","159891","VXUS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2613227499","title":"国金证券：国内制药供应链景气度上行持续 建议把握CXO行业两大核心主线","url":"https://stock-news.laohu8.com/highlight/detail?id=2613227499","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2613227499?lang=zh_cn&edition=full","pubTime":"2026-02-22 18:59","pubTimestamp":1771757953,"startTime":"0","endTime":"0","summary":"展望2026年，建议把握优先布局行业龙头及聚焦海外业务占比高的标的两大CXO行业核心主线。国内企业密集布局并通过BD合作落地出海，成为全球药企核心合作标的。制药供应链：景气度上行持续，新技术方向带动产业扩容2025年以来，AI制药技术热度攀升、全球创新药景气度延续，再叠加国内生物医药投融资触底回升，行业市场关注度持续走高，基本面复苏趋势愈发明确。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1406188.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0276","BK0201","BK0183","600109","BK0188","BK0012","BK0028","BK1574","01477","BK1191","CXO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2608306028","title":"国信证券：小核酸CXO行业景气度持续攀升 迈入临床兑现与商业化加速阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2608306028","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608306028?lang=zh_cn&edition=full","pubTime":"2026-02-02 14:30","pubTimestamp":1770013847,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，国信证券发布研报称，小核酸CXO作为小核酸药物产业的核心支撑，受益于技术突破与商业化加速，行业景气度持续攀升。小核酸CXO行业同步进入发展快车道，形成“研发服务-中试放大-商业化生产”的CRDMO全链条服务体系。报告中称，小核酸药物正迎来全球范围内的蓬勃发展期，已从技术验证阶段迈入临床兑现与商业化加速阶段。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1400480.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0028","CXO","BK0276","BK0183","BK0188","002736"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2606930347","title":"国联民生证券：全球CXO行业强势复苏 2026年有望延续高景气","url":"https://stock-news.laohu8.com/highlight/detail?id=2606930347","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606930347?lang=zh_cn&edition=full","pubTime":"2026-01-28 15:58","pubTimestamp":1769587104,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，国联民生证券发布研报称，全球生物科技及药企投融资活动及交易需求在2025年显著回暖，创新药新技术平台蓬勃发展，驱动CXO行业下游需求全面复苏，行业景气度有望将、在2026年延续。中国市场IND数量同比增长19%，BD交易金额同比高增，国内创新药市场活力充沛，为CXO行业提供持续动能。国内临床CRO明确拐点，泰格医药受益行业复苏中国CRO市场于2025年重回增长轨道。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1398498.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["601456","BK1147","161027","01456","BK0276","CXO","BK1564"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2605449493","title":"近五成生物医药公司业绩预喜 多家CXO企业表现亮眼","url":"https://stock-news.laohu8.com/highlight/detail?id=2605449493","media":"南方财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605449493?lang=zh_cn&edition=full","pubTime":"2026-01-23 08:24","pubTimestamp":1769127883,"startTime":"0","endTime":"0","summary":"南方财经1月23日电，据中证报，截至1月22日，按照申万一级行业划分，已有逾50家生物医药企业披露2025年业绩预告，27家预喜，预喜比例近五成。值得关注的是，多家CXO（医药外包服务，包括CDMO和CRO）公司业绩表现亮眼。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601233628152649.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["399441","161726","BK4585","BK4588","CXO","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2603955152","title":"西南证券：CXO行业关注新分子的成长性与国内景气度修复的传导","url":"https://stock-news.laohu8.com/highlight/detail?id=2603955152","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603955152?lang=zh_cn&edition=full","pubTime":"2026-01-16 10:37","pubTimestamp":1768531037,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，西南证券发布研报称，CXO板块持续关注：1）全球市场多肽、偶联药物、寡核酸等新分子对R、D、M外包持续注入的增长动能；2）地缘风险不确定性出清后的反转与板块情绪面改善；3）国内市场景气度修复、创新药研发需求的传导；4）AI赋能的药物研发。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1393688.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0183","BK0028","600369","BK0012","CXO","BK0276","BK0188"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.concho.com","stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":0},{"period":"3month","weight":0},{"period":"6month","weight":0},{"period":"1year","weight":0},{"period":"ytd","weight":0}],"compareEarnings":[{"period":"1week","weight":0.0535},{"period":"1month","weight":0.0486},{"period":"3month","weight":0.0059},{"period":"6month","weight":0.0512},{"period":"1year","weight":0.2881},{"period":"ytd","weight":0.0184}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Concho Resources Inc.成立于2006年2月22日，是一家于2006年2月在特拉华州注册成立的公司，是一家独立的石油和天然气公司，从事石油和天然气资产的收购、开发、勘探和生产。","yearOnYearQuotes":[{"month":1,"riseRate":0.714286,"avgChangeRate":0.054246},{"month":2,"riseRate":0.384615,"avgChangeRate":-0.002949},{"month":3,"riseRate":0.692308,"avgChangeRate":0.024071},{"month":4,"riseRate":0.769231,"avgChangeRate":0.069872},{"month":5,"riseRate":0.384615,"avgChangeRate":-0.030229},{"month":6,"riseRate":0.461538,"avgChangeRate":0.004495},{"month":7,"riseRate":0.692308,"avgChangeRate":0.012949},{"month":8,"riseRate":0.461538,"avgChangeRate":-0.02419},{"month":9,"riseRate":0.571429,"avgChangeRate":0.015298},{"month":10,"riseRate":0.5,"avgChangeRate":0.017047},{"month":11,"riseRate":0.571429,"avgChangeRate":0.047858},{"month":12,"riseRate":0.642857,"avgChangeRate":0.007299}],"exchange":"NYSE","name":"康休","nameEN":"Concho Resources"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.41.0","shortVersion":"4.41.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"康休(CXO)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供康休(CXO)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"康休,CXO,康休股票,康休股票老虎,康休股票老虎国际,康休行情,康休股票行情,康休股价,康休股市,康休股票价格,康休股票交易,康休股票购买,康休股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"康休(CXO)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供康休(CXO)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}